AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 162 min read$LGND

Haas Jason sold $1.7M of LGND

Haas Jason sold 6,461 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $255.58 ($255.01–$256.08, $1.65M total) across 2 trades on 2026-06-12.

Original reporting
SEC EDGAR · Haas Jason
Published Jun 16, 2026, 1:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LGND
Neutral
medium confidence
Mentioned
$LGND
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but this specific disclosure does not include any operational or financial update for the company.

02

Market read

A director’s open-market sale at ~$255.58/share is a modest sentiment datapoint without accompanying company news.

03

What to watch

No 10b5-1 plan is indicated, but the article also lacks context on prior holdings, total compensation, or whether other insiders/owners are buying or selling.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-15 for a 2026-06-12 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals (director Haas Jason).

Company-level read

Ticker impact

$LGNDNeutralMedium confidence
Context

Ligand Pharmaceuticals director Haas Jason sold 6,461 shares in open-market transactions at ~$255.58/share, per SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan stated and no accompanying company-specific news (earnings, guidance, trials, deals).

Market effects

Sector

Minimal; single-insider sale does not reset sector expectations for biotech/pharma.

Regional

None indicated; US-listed filing only.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals (taxes, diversification, planned liquidity) since the article provides no stated reason and only shows a director’s transaction.

Key entities

  • issuer
    LGND

    Ligand Pharmaceuticals Inc., the company whose director transaction is disclosed.

  • insider
    Haas Jason

    Director of Ligand Pharmaceuticals who sold shares via open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LGND insider trading history →

Related articles

SEP 4
$LGNDHighAI 8/10

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.

insidermonkey.com3 min
AUG 13
$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min
AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min
AUG 6
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, F

SEC EDGAR 8-K6 min
JUL 14
$LGNDMedAI 9/10

XOMA Royalty Announces Closing of Its Acquisition by Ligand

XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.

manilatimes.net2 min
JUL 14
$LGNDMedAI 9/10

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty for $39.00 per share in cash, totaling about $739 million equity value, plus one CVR per share tied to 75% of net litigation proceeds. The deal adds seven commercial products and 100+ development assets, expanding its portfolio to 200+ royalties. Expected EPS accretion: +$0.50 (2026) and +$1.50 (2027).

manilatimes.net3 min